GRI Bio, Inc. (GRI)

In December 2025, the company closed an $8.0 million public offering. In January 2026, GRI Bio raised an additional $6.5 million through an At The Market offering and a 1-for-28 reverse stock split became effective. The U.S. Patent and Trademark Office issued a patent for a distinct class of proprietary compounds in January 2026. The stock experienced a surge after positive gene expression data for its IPF drug candidate was reported. In February 2026, GRI Bio reiterated its full-year 2025 financial results and highlighted key clinical and corporate achievements. In March 2026, despite reporting additional positive data from its Phase 2a study in IPF, the stock slumped by 20%. In April 2026, the company received a Notice of Allowance for a UAE Patent Application. The stock has experienced a significant decline over the past year, with a 96.28% drop between May 2, 2025, and April 30, 2026.

As a clinical-stage biopharmaceutical company, GRI Bio, Inc.'s revenue generation is primarily tied to the progression of its drug candidates through clinical trials and potential future commercialization, so there is no indication of demand seasonality.

GRI Bio, Inc. is a clinical-stage biopharmaceutical company in the Healthcare sector and Biotechnology industry, focusing on drug discovery. Its major product candidates include GRI-0621, an oral inhibitor of type 1 Natural Killer T (NKT) cells in Phase IIa clinical trials for severe fibrotic lung diseases like IPF. GRI-0803, a novel oral agonist of type 2 Natural Killer T (NKT) cells, is in preclinical development for autoimmune disorders like SLE. The company also has a proprietary library of over 500 compounds.

GRI Bio, Inc. is headquartered in La Jolla, California, United States. While it has a notice of allowance for a UAE patent application, its core operational footprint is concentrated in the United States.

Information specifically detailing GRI Bio, Inc.'s brand reputation is limited. Retail sentiment on platforms like Stocktwits has shown "extremely bullish" trends despite stock drops, suggesting positive sentiment among some retail investors.

GRI Bio, Inc. has a limited number of institutional owners, with 8 holding a total of 59,526 shares as of May 1, 2026. Major institutional shareholders include Geode Capital Management, Llc, Vanguard Group Inc, and StoneX Group Inc. Individual insiders hold a very small percentage of the company's shares. Key executives who are also shareholders include W. Marc Hertz, Leanne Kelly, Albert Agro, and Vipin Kumar.